Common stock, no par value
- Symbol
- IMDX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
IMDXNASDAQEQUITYCurrent
Item 2.02 Results of Operations and Financial Condition. On November 16, 2026, Insight Molecular Diagnostics Inc. (“we,” “us,” “our,” the “Company” or “iMDx”) issued a press release announcing our financial results for the three and nine months ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1, which, in its entirety, is incorporated herein by reference.…
Press release in this filing
IMDx Reports Third Quarter 2026 Results and Provides Corporate Update →Insight Molecular Diagnostics Inc. · 8-K · Filed 2026-11-16
Exhibit 99.1 IMDx Reports Third Quarter 2026 Results and Provides Corporate Update Progress with FDA review of GraftAssureDx and its planned response to FDA’s request for additional information Initiated enrollment into GALACTIC registry study from UCLA Medical Center Revenue from GraftAssureCore lab-developed test expected to build as GALACTIC enrollment grows Q3 2026 revenue of $559,000; operating expenses decline as FDA-submission costs wind down iMDx appoints veteran transplant sales leader to prepare for GraftAssureDx commercial launch NASHVILLE, Tenn., Nov. 16, 2026 - Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its third quarter results: Fellow shareholders, Innovation and disruption in diagnostics tend to follow a well-known path: A new test starts in a specialized laboratory, becomes used more widely, and eventually becomes a broadly available kit that can be run at local laboratories. There are countless examples of familiar tests that have progressed toward simpler, more accessible test kits. In this classic story of decentralization, we believe that our …
Open exhibit ↗